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ABSTRACT  
Purpose: Low-grade serous ovarian carcinoma (LGSC) responds poorly to chemotherapy and 
is characterised by activating mutations in the RAS-MAPK pathway, including oncogenic 
BRAF. However, response to BRAF inhibitors is tumor-type specific. Significant improvement 
in survival is seen in patients with BRAF-mutant melanoma, but other cancer types, such as 
colorectal cancers, are generally less sensitive. We examined the frequency and characteristics 
of BRAF-mutated LGSC and describe response to treatment with BRAF inhibitors. 
Patients and Methods: Mutations were assessed in LGSC (n=65) using targeted, exome and 
whole genome sequencing. Patient characteristics, treatment and clinical outcome were 
assessed, with a median follow-up time of more than 5 years. BRAF inhibitors were trialed in 
two patients with a somatic BRAFV600E mutation, one on Dabrafenib monotherapy, monitored 
clinically, biochemically (CA125 levels) and with PET imaging. Expression of BRAFV600E 
protein in this patient was assessed by immunohistochemistry. 
Results: Amongst LGSC cases, 9/65 (13.8%) had a somatic BRAF mutation. Of the nine cases 
with BRAF mutation-positive LGSC, four relapsed with progressive disease and did not 
respond to conventional chemotherapy. Two of the patients progressed quickly and died due 
to progression of their disease, and two received targeted treatment. Two patients with 
BRAFV600E mutation received BRAF inhibitors at relapse and both achieved durable responses.   
Conclusion: BRAF mutations are not uncommon in patients with LGSC and should be 
routinely tested as BRAF inhibitors can be an effective treatment for these patients. The results 
highlight the need for targeted treatment in this rare tumor type and a prospective study is 
needed to formally assess the response rate and clinical benefit.  
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INTRODUCTION 
Epithelial ovarian cancer (EOC) is a heterogeneous disease comprising several histological and 
molecular subtypes, and emerging molecular analyses are challenging longstanding clinical 
treatment paradigms. EOC subtypes are characterised by different gene expression and somatic 
mutation patterns and varying degrees of sensitivity to current standard carboplatin/paclitaxel 
combination chemotherapy.1-3 The predominant type of EOC is serous carcinoma, accounting 
for approximately 80% of cases. Serous carcinoma is further classified into two main subtypes: 
the more common and better-characterised high-grade serous carcinoma (HGSC), and the less 
common low-grade serous carcinoma (LGSC). LGSC is not generally responsive to standard 
platinum-based chemotherapy,4,5 and outcome is poor in women with residual disease 
following debulking surgery,6,7 underscoring the need for alternative therapeutic options. 
LGSC is molecularly distinct from HGSC and is characterised by activating mutations of the 
RAS-MAPK pathway, displays few genomic changes and is typically TP53 wild-type.8-11 
Oncogenic BRAF mutations, such as V600E, lead to constitutive activation of the MAPK 
pathway and can be found in several cancer types, most commonly in melanoma.12 The 
reported frequency of BRAF mutations in LGSC varies from 2% to 33% 10,13-15 and they are 
also found in up to 46% of serous borderline tumors.16,17 
Clinical trials have shown impressive response rates to BRAF inhibitors in BRAF mutant 
melanoma, and their use in metastatic melanoma is now considered standard of care.18,19 
Responses in other tumor types, including gastrointestinal stromal tumor, thyroid papillary 
cancer, hairy cell leukaemia and high-grade colorectal neuroendocrine tumors have also been 
reported.20-25 However, some cancers types, such as colorectal adenocarcinoma have much 
lower response rates to BRAF inhibitors despite having the same somatic BRAF mutations.26-
28 Therefore, while oncogenic BRAF represents a potential therapeutic target, responses vary 
according to tumor type and clinical benefit is not always achieved. This has led to large 
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‘basket’ trials assessing response to BRAF inhibitors in multiple BRAF mutant cancers.29 
However definitive conclusions from assessment of response in rare tumor types remains 
difficult due to small patient numbers. 
We present the characterisation of BRAF mutations in LGSC patients, including two patients 
with BRAFV600E mutation who demonstrated substantial clinical, biochemical and radiological 
responses following treatment with BRAF inhibitors.  
METHODS  
The study population consisted of women diagnosed with LGSC between 1992 and 2015 
(n=65). The women were identified in the Australian Ovarian Cancer Study (AOCS, 
http://www.aocstudy.org) or the Gynaecological Oncology Biobank at Westmead Hospital 
(GynBiobank) (Sydney, NSW). We incorporated the shift from a three tier grading system to 
a two tier grading system, as recommended in the 2014 World Health Organization (WHO) 
classification of ovarian tumors.30 LGSC cases were identified from review of diagnostic 
pathology reports and independent review of hematoxylin and eosin (H&E) stained 
diagnostic slides by expert Gynae-pathologists. In addition, grade 2 cases were screened for 
TP53 mutations and only those found to be wildtype, consistent with a molecular 
classification of LGSC, were included in the LGSC cohort. 
Clinical Definitions.  
Progression-free survival (PFS) was calculated as the time interval from date of histological or 
cytological diagnosis to the date of first progression based on Gynecological Cancer Inter 
Group (GCIG) criteria.31 Overall survival (OS) was calculated from date of diagnosis to date 
of death from any cause. Treatment response was assigned according to GCIG CA125 
criteria.31 Briefly, ≥50% reduction in serum CA125 from an elevated pretreatment level, 
confirmed and maintained for at least 28 days was considered a response. The reverse Kaplan-
Meier method was used to quantify follow-up time. 32 
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Study Oversight.  
Women recruited to AOCS and the GynBiobank provided written consent. AOCS was 
approved by the Human Research Ethics Committee at the Peter MacCallum Cancer Centre, 
Queensland Institute of Medical Research, Westmead Hospital and all other participating 
hospitals. The GynBiobank and this study were approved by the Western Sydney Local Health 
District Human Research Ethics Committee.  
Written informed consent was additionally obtained from the patient treated with dabrafenib 
to include clinical information and imaging, also approved by the Western Sydney Local 
Health District Human Research Ethics Committee.  
Sequencing and Immunohistochemistry.  
Frozen or fixed tumor samples were sectioned, H&E stains were used to assess tumor content 
before and after serial sectioning for nucleic acid extraction. For samples containing >70% 
tumor, 1 x 100 μm section were used for DNA extractions. For samples containing <70% 
tumor, needle dissection of tumor cells was performed on up to 50 x 10 μm sections. 
Extractions were performed using the DNeasy Blood and Tissue kit or QIAamp DNA Mini Kit 
(Qiagen, Hilden, Germany). DNA was quantified using the Qubit® dsDNA BR assay 
(Invitrogen, Carlsbad, CA, USA).  
Targeted multigene sequencing. Mutations in exon 15 of BRAF, exon 2 of KRAS, exon 20 of 
ERBB2 and exons 2-11 of TP53 were screened using high-resolution melt (HRM) analysis and 
validated by direct sequencing as previously described.8,33 A subset of cases was screened by 
next-generation sequencing. Target enrichment of the DNA samples was performed according 
to the manufacture’s protocol (Qiagen GR DNAseq Targeted Panels V2 Handbook 06/2015 
protocol; NGHS-006x Human Ovarian Cancer Panel). The PCR reactions for each sample were 
pooled and target enriched DNA were purified using Agencourt AMPure XP beads (Beckman 
Coulter, Indianopolis, Indiana, USA). The DNA Libraries were prepared following Qiagen 
8 
 
QIAseq 1-Step Amplicon Library Preparation Handbook 01/2016. DNA libraries (> 4 nM) 
were sequenced on a MiSeq (Illumina, Australian Genome Research Facility, Melbourne) read 
length 2 x150 bp. Sequencing coverage read depth of 1200x was achieved for each sample.  
Exome and whole genome sequencing. Whole genome and exome sequencing data and 
analysis was obtained for 22 cases using snap frozen tumor tissue and matched normal DNA 
from peripheral blood lymphocytes as previously described.33,34 
Immunohistochemistry. Samples of the ovarian tumor from the primary surgery specimen and 
in biopsies at disease relapse, were stained for mutated BRAFV600E using a mutation specific 
monoclonal antibody (mouse anti-human BRAFV600E monoclonal antibody (clone VE1), 
Spring Biosciences, Pleasanton, CA, USA) using the Ventana BenchMark ULTRA IHC 
staining module with a 1 in 200 antibody dilution and reviewed by a pathologist (RB). 
RESULTS 
Frequency of BRAF mutations in LGSC  
BRAF-mutation-positive cases were identified among a LGSC cohort of 65 patients 
(WES/WGS, n = 22; targeted multigene sequencing, n = 43). Molecular characterisation 
revealed 9/65 (13.8%) to have a BRAF mutation. Representative photomicrographs of the 
BRAF-mutation positive cases are shown in Figure 1. Most were BRAFV600E (8/9, 89%), a 'hot-
spot' mutation locus in diverse cancer types, and one had a BRAFL597R mutation, an uncommon 
missense variant (Table 1).  
In three BRAF mutant cases whole exome and whole genome sequencing additional variants 
predicted to alter protein sequence (ranging from 13 to 30 per case, Table 2) at lower allele 
frequencies compared with the BRAF mutations, suggestive of sub-clonal events.33 There was 
no evidence of additional driver mutations and we found no genes with deleterious mutations 
that were common to the three cases, apart from BRAF.  
Clinical features of BRAF-mutation positive LGSC cases 
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Among BRAF-mutation positive LGSC cases, patient age at diagnosis ranged from 22 to 77 
years (median 51 years) (Table 1). The majority had FIGO stage III or IV disease at diagnosis 
(7/9, 78% patients). 
All patients with BRAF-mutated LGSC had surgery as part of primary treatment and most were 
optimally debulked to no macroscopic residual disease (7/9, 78%). The median follow-up time 
was 61.5 months and five of the nine cases (56%) have remained progression-free (Table 1). 
Treatment and clinical course in patients with BRAF-mutation positive LGSC following 
disease progression  
Four patients progressed and all had a relatively short PFS (Table 1, Figure 2). None of these 
four patients responded to chemotherapy in the relapsed setting. The first two patients, Case 6 
and Case 8 (Table 1) were treated with conventional chemotherapy and had poor overall 
survival (Figure 2A and Figure 2B), in contrast with two patients who received targeted 
treatment (Figure 2C and Figure 2D). 
Case 6 was a 51-year-old woman diagnosed with stage IIIC LGSC, who was optimally 
debulked to no residual macroscopic disease (Figure 2A). The patient progressed within 5 
months of completing primary carboplatin and paclitaxel chemotherapy, and was commenced 
on second line chemotherapy with pegylated liposomal doxorubicin (Caelyx). There was no 
response by CA125 criteria31 and the patient subsequently received third line etoposide 
chemotherapy but progressed and died two months after the completion of treatment, resulting 
in an overall survival of less than two years from her initial diagnosis. 
Case 8 was diagnosed with stage IV ovarian cancer at age 31 (Figure 2B). She received 3 cycles 
of neoadjuvant chemotherapy (carboplatin / paclitaxel) with no significant response by CA125 
criteria. She proceeded to surgery and was debulked to ≤ 1 cm residual disease, with pathology 
confirming Grade 1 serous carcinoma arising from borderline serous cystadenoma. After a 
further 5 cycles of carboplatin and paclitaxel her CA125 decreased (51 U/ml) but did not 
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normalise. Disease progression was evident within two months of completing chemotherapy, 
with CA125 increasing to 502 U/ml, and the patient died a month later, less than a year from 
diagnosis. 
Case 4 was a 22-year-old who presented with abdominal pain. Pelvic ultrasound revealed a 
complex ovarian mass and serum CA125 was significantly elevated (647 U/mL; normal range 
<35 U/mL). At surgery the patient was found to have widespread peritoneal disease and 
histopathology revealed a serous borderline tumor with invasive implants throughout the 
peritoneum, FIGO stage IIIB. She was debulked to no macroscopic residual disease and despite 
six cycles of chemotherapy with carboplatin and paclitaxel, her CA125 level remained elevated 
(38 U/mL) at the end of primary treatment (Figure 2C), indicative of chemo-resistant residual 
disease. 
Eleven months later imaging confirmed progressive LGSC resulting in secondary debulking 
surgery and further chemotherapy. At further progression, the patient was entered into a phase 
I trial of the BRAF inhibitor dabrafenib20 (GlaxoSmithKline, Australia) and received 100 mg 
bi-daily (bd).  Her best RECIST 1.135 response during the trial was stable disease with a 28% 
decrease of the target lesion. During the study, an interruption in dabrafenib for toxicity, 
resulted in a CA125 spike to 238 U/ml, which promptly decreased following resumption of 
dabrafenib. After 10 months of dabrafenib therapy, the patient came off study due to a 
combination of toxicity and progressive disease.  
With subsequent further disease progression, the patient received chemotherapy with 
carboplatin/gemcitabine and liposomal doxorubicin but there was no response by CA125 
criteria. 
At the time of disease progression following chemotherapy, biopsy of supraclavicular and para-
aortic lymph node confirmed the presence of BRAFV600E mutation by immunohistochemistry 
(Figure 3B, 3C), and she was recommenced on dabrafenib via a compassionate access scheme.  
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On therapy with dabrafenib 150 mg bd, (50% higher than her previous dose), there was an 
impressive clinical response, with reduced analgesic requirements, improved well-being and 
marked reduction in the palpable SCF lymph node. After seven months of therapy, her CA125 
fell to within the normal range, for the first time since diagnosis. A PET/CT scan confirmed a 
significant partial radiological response to treatment (63% decrease in sum of diameters of 
measured lesions) and significantly less metabolically active lesions throughout almost all 
nodal regions and pulmonary nodules (Figure 4). 
At the time of censoring for this report the patient was still on dabrafenib and the CA125 had 
remained within normal range for 4 months, confirming a complete CA125 response according 
to GCIG CA125 criteria.31 
The final patient, Case 9, was a 71-year-old woman who was diagnosed with stage IV disease 
at diagnosis with a pleural effusion and CA125 was elevated at 275 U/ml (normal <36 U/ml). 
She received one cycle of neoadjuvant carboplatin and paclitaxel prior to being admitted with 
a bowel obstruction and undergoing debulking surgery. Histopathology confirmed LGSC and 
mutation testing revealed a BRAFV600E mutation. On progression, she was enrolled into a BRAF 
inhibitor basket trial (manuscript in preparation) and has been on treatment for over 12 months. 
This patient had a partial radiological response (personal communication, Bo Gao) and 
normalization of her CA125 on treatment with a BRAF inhibitor (Figure 2D). 
DISCUSSION  
We report here clinical outcomes in one of the largest series of patients with BRAF-mutation 
positive LGSC reported to date and, for the first time to our knowledge, report response to the 
BRAF inhibitor, dabrafenib, in a patient with LGSC with a somatic BRAFV600E mutation.  
LGSC is typically TP53 wild-type and commonly harbors RAS and RAF pathway 
mutations.8,13,17 This finding has led to clinical trials evaluating MEK inhibitor activity. A 
phase 2 trial evaluating response to MEK inhibitor, selumetinib in LGSC reported a promising 
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response rate of 15%.36 Response was not associated with known BRAF/KRAS mutation status, 
although this may be due to the small number of cases with known mutations in the trial. It is 
not clear whether all mutation subtypes of LGSC respond similarly to MEK inhibition.  
We found BRAF mutations in 13.8% (9/65) of LGSC, which falls within the broad range 
reported previously (2% - 33%).10,13-15,37 This was similar to 17.9% (10/56) reported by Xing 
et al37 in a similar sized cohort and slightly higher than AACR GENIE Project database, where 
the frequency of patients with BRAF mutations in the LGSC was 4/56 (7%, accessed April, 
2017).38 The GENIE Project contains genomic records generated in CLIA-/ISO-certified 
laboratories obtained at multiple tertiary referral centers38, and may be enriched for patients 
with late stage disease seeking biomarker-driven clinical trials, whereas the patients reported 
in the current study are prospectively recruited clinic-based cases.   
Some studies have suggested that BRAFV600E mutations in LGSC are rare and associated with 
early stage disease and improved prognosis.14,15,39 However, we found that most women with 
a BRAF mutation positive tumor were diagnosed at an advanced stage. In our cohort, most 
women were able to be debulked to no residual disease, which is associated with improved 
prognosis. However, in the relapse setting BRAFV600E mutation positive LGSC was not 
responsive to chemotherapy. Four of the nine BRAF mutation positive patients identified 
progressed soon after primary treatment. All responded poorly to chemotherapy, which is 
characteristic of LGSC.4,5 Two received conventional treatment and died within two years of 
diagnosis. Two received BRAF inhibitors and both achieved sustained response.  
Case 4 had initially received dabrafenib as part of a dose-finding phase I trial20 and while some 
response was seen, indicated by deceased serum CA125 levels, a much more profound response 
was seen when the patient was re-treated with dabrafenib 46 months later. The explanation for 
improved response with subsequent dabrafenib treatment is potentially multifactorial and may 
include the increased dosage, in line with current melanoma dosing guidelines, possibly 
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suggesting that her original dose was sub-therapeutic.40 The patient also had a 25 kg weight 
loss between dabrafenib treatment periods, although there is no evidence to date that dabrafenib 
dose requires adjustment for weight.40 There is also emerging evidence that BRAF inhibitors 
may act in part via an effect on host immunity41,42, and it is possible that an uncharacterised 
immunological component contributed to response in this patient. 
Consistent with our findings, responses to another BRAF inhibitor vemurafenib, have been 
reported in LGSC. Combe et al reported a response in a similarly heavily pre-treated woman 
who achieved a durable partial response to vemurafenib according to RECIST and CA125 
criteria for over 21 months43. Similarly, in a large basket trial of vemurafenib in multiple cancer 
types, the one patient with LGSC also showed a sustained (over 12 months) partial response to 
vemurafenib,29 Case 9 was also the only LGSC patient in a basket trial of a novel BRAF 
inhibitor (manuscript in preparation) and has shown a sustained response, providing additional 
evidence that LGSC patients with BRAFV600E mutation-positive tumors are broadly responsive 
to BRAF inhibition. 
In conclusion, recurrent LGSC is relatively chemotherapy resistant and targeted treatment may 
play an important role in improving patient outcome. Our results are consistent with recent 
reports of response to BRAF inhibition in at least two other studies 29,43 and suggest that BRAF 
inhibitors may be an effective option in patients with relapsed, BRAF-mutation positive LGSC. 
Moreover, the frequency in which these mutations were detected, indicates the importance of 
routine molecular testing for BRAFV600E mutations in all advanced LGSC. The results also 
highlight the need for novel clinical trial design, such as platform trials, as traditional clinical 
trials are unlikely to be effective in identifying effective treatments for rare ovarian cancer 
subtypes. 
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FIGURE LEGENDS 
Figure 1. Representative histological sections of BRAF-mutated LGSC cases. Sections (4 
μm) from formalin fixed, paraffin embedded tumor tissue blocks were stained with 
Hematoxylin and Eosin. (A) Case 1, Publishing ID 65928; (B) Case 2, Publishing ID 11368; 
(C) Case 3, Publishing ID 5711; (D) Case 4, Publishing ID 65917; (E) Case 5, Publishing ID 
65854; (F) Case 6, Publishing ID 10693; (G) Case 7, Publishing ID 9125; (H) Case 8, 
Publishing ID 11014; (I) Case 9, Publishing ID 66198. 
 
Figure 2. The serum CA125 levels and treatment throughout the clinical course of patient (A) 
Case 6, Publishing ID 10693; (B) Case 8, Publishing ID 11014; (C) Case 4, Publishing ID 
65917 and (D) Case 9, Publishing ID 66198.  
 
Figure 3. Expression of BRAFV600E in Case 4. Immunohistochemical staining using an 
antibody specific for BRAFV600E in formalin fixed, paraffin embedded tumor tissue sections of 
(A) Left ovarian tumor from the primary surgical specimen (B) Left supraclavicular fossa 
lymph node core biopsy prior to second dabrafenib treatment at 78 months (C) Left para-aortic 
lymph node core biopsy prior to second dabrafenib treatment at 78 months.  The bar indicates 
50 µm scale.   
 
Figure 4. PET images of Case 4. 18-F-FDG PET/CT (Siemens Biograph mCT) images prior 
to (A, B and C) and after 7 months of second dabrafenib treatment (D, E and F) indicating 
response to treatment with decrease in size and metabolic activity of lesions. The green arrows 
indicate physiological uptake in heart, kidneys and bladder. 
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The axial images of the left medial supraclavicular and deep paravertebral lesions prior to (B) 
and after 7 months of second treatment with dabrafenib (E). The right common iliac node prior 
to (C) and after 7 months of second treatment with dabrafenib (F).  
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